Fortitude to go public via HeartSciences reverse merger as HSCS spikes 91%
The all-stock deal targets a Nasdaq listing under TUDE, pending approval, and includes a 157,000 ZEC annualized run-rate disclosure.
Zcash miner Fortitude Mining Holdings agreed to an all-stock reverse merger with Nasdaq-listed HeartSciences, aiming to become publicly traded without a traditional IPO. HeartSciences shares jumped as much as 91% intraday Tuesday as the market priced the shell’s new path to a Fortitude-led listing under the expected ticker TUDE, subject to regulatory approval.
Key Takeaways
- An all-stock reverse merger with Nasdaq-listed HeartSciences gives Fortitude Mining Holdings a fast-track route to public markets without a traditional IPO.
- Fortitude’s management team is expected to control the combined company, which plans to operate under the Fortitude name and seek a Nasdaq ticker change to TUDE pending regulatory approval.
- HSCS rose as much as 91% intraday Tuesday after the announcement and continues trading under HSCS until the transaction closes.
- Fortitude disclosed a 157,000 ZEC annualized production run-rate as of May 31, while HeartSciences reported a fiscal 2025 net loss of $8.77 million on minimal revenue.
HSCS Rips on Reverse-Merger Plan to List Fortitude on Nasdaq
HeartSciences and Fortitude Mining Holdings agreed to an all-stock transaction structured as a reverse merger, positioning Fortitude to become publicly traded without running a traditional IPO process.
The immediate trade was in the public shell. HeartSciences shares (HSCS) gained as much as 91% intraday Tuesday, according to Google Finance data. The stock continues to trade under HSCS pending completion of the transaction, keeping event-driven flows concentrated in the existing Nasdaq-listed vehicle while the future Fortitude listing remains conditional.
The combined company is expected to operate under the Fortitude name and trade on Nasdaq under the ticker TUDE, subject to regulatory approval. That approval and the closing itself are the gating items, which matters because the price action has already front-run the corporate mechanics.
How the All-Stock Structure Shifts Control and Ownership
The deal is all-stock, meaning consideration is paid in shares rather than cash. In practice, that structure typically shifts the debate from near-term financing to who controls the post-close cap table and what the market is actually buying when it trades the pre-close ticker.
Fortitude’s management team is expected to assume control of the combined company. Existing HeartSciences shareholders will retain a minority ownership stake after the merger, leaving them with diluted but ongoing exposure to a publicly traded entity.
HeartSciences’ healthcare unit is expected to continue operating under CEO Andrew Simpson’s leadership after the transaction. Simpson framed the rationale as an escape from “the constant cycle of raising capital,” a line that reads less like a growth pivot and more like a capital-markets reset for a company that has struggled to fund itself on its current trajectory.
Fortitude’s ZEC Run-Rate Disclosure vs. HeartSciences’ Financial Snapshot
Fortitude is privately held and disclosed little beyond a single operating metric: annualized production scaled to 157,000 Zcash (ZEC) as of May 31. With ZEC trading around $413 at publication time, per CoinMarketCap data, the token’s implied market cap was about $6.92 billion. The packet includes no mining cost structure, hashrate, treasury, or profitability detail, which limits how cleanly traders can map the equity event to ZEC exposure.
HeartSciences’ financial snapshot is clearer and not flattering. The company generated minimal revenue in fiscal 2025 and posted a net loss of $8.77 million, widening from a $6.61 million loss a year earlier, per MarketScreener. It also launched its MyoVista Insights software platform in fiscal 2025, described as designed to modernize existing ECG management systems.
Signals to Watch for Fortitude Zcash miner to list via
The first gating item is regulatory approval for the combined company’s expected Nasdaq ticker TUDE and listing status. Until that clears, the market is trading a plan, not a completed listing.
Deal documents are the next critical input. Any filings that disclose the exchange ratio, valuation, and pro forma ownership beyond the statement that HSCS shareholders will be minority owners will determine whether HSCS’s move can be anchored to terms rather than headlines.
A stated closing timeline, or delays, will matter for positioning because HSCS is expected to continue trading under HSCS until completion. The longer the gap, the more room there is for volatility and for the market to reprice on incremental information.
Finally, traders will need more from Fortitude than the 157,000 ZEC annualized production figure. Additional disclosures on costs, balance sheet, and operating scale would change how the post-merger entity gets modeled and whether the equity becomes a credible proxy for ZEC-linked mining exposure.
Event-Driven Setup in HSCS, With TUDE Approval as the Next Catalyst
I treat this as an event-driven setup first and a fundamentals trade second. The tradeable catalyst is the public shell’s volatility, and the 91% intraday HSCS reaction shows how quickly that vehicle can reprice on a reverse-merger headline.
The threshold that matters is whether definitive terms and approvals arrive fast enough to convert this from narrative to structure. If TUDE approval and a clean close land alongside real Fortitude financial disclosure, the setup starts to look structural rather than headline-driven, and the market can price the post-merger entity on something other than the shell’s optionality.
